Intravenous liraglutide improved AD-like learning and memory deficits, lowered the level of tau protein hyperphosphorylation, and reduced neurodegeneration, by strengthening JNK and ERK signaling pathways and boosting o-glycosylation of neuronal cytoskeletal proteins in STZ mice (Xiong et al., 2013). Here, MAPT is linked to Alzheimer disease.